Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Perren
P Matter

Showing results (161-170 of 164) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 164 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2007
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trialA Di Leo, M Tanner, C Desmedt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2001
Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancerC J Poole, T Perren, A Burton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2011
A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancerG Rustin, N Reed, G C Jayson, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 13, 2016
Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UKL Khoja, K Nolan, R Mekki, et al.
Pageof 17

Showing results (161-170 of 164) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 164 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2007
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trialA Di Leo, M Tanner, C Desmedt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2001
Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancerC J Poole, T Perren, A Burton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2011
A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancerG Rustin, N Reed, G C Jayson, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 13, 2016
Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UKL Khoja, K Nolan, R Mekki, et al.
Pageof 17